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In structure, ghrelin resembles motilin. The two peptides are considered to be members of the motilin-ghrelin peptide family.
Motilin is considered to be an endocrine regulator of the interdigestive migrating contractions, the fasted motor pattern in the
gastrointestinal (GI) tract. It has been reported that ghrelin stimulates GI motility. The gastrokinetic capacity of ghrelin has been
well documented in the rodent. However, there have been few positive reports of the gastrokinetic capacity of ghrelin in dogs.
Some reports with human subjects have shown that an i.v. ghrelin injection accelerated gastric emptying of a meal and improved
meal-related symptoms. These results suggest that ghrelin has potential as a prokinetic. However, it seems unlikely that plasma
ghrelin would play a physiological role in these digestive physiological events and stimulate gastric emptying, as these outcomes
would appear to be in contradiction with the suppression of the endogenous release of ghrelin after eating. The physiological roles
of ghrelin need to be clariﬁed.
1.Introduction
Ghrelin is a 28-amino-acid peptide predominantly produced
by endocrine cells in the oxyntic mucosa of the stomach
as an endogenous ligand for the growth hormone (GH)
secretagogue receptor [1–4]. Initially, ghrelin was identiﬁed
as having properties related to the release of GH [5].
Studies have shown that the infusion of ghrelin increases
circulating plasma GH in rodents and humans [6–10].
However, other actions of ghrelin have emerged, such as
its eﬀects on the glucose metabolism and insulin release
[11, 12], cardiovascular actions [13, 14], and food intake and
control of energy balance [15, 16].
Structurally, ghrelin resembles motilin. Motilin is a 22-
amino-acid peptide synthesized from endocrine cells of the
duodeno-jejunal mucosa. Motilin and ghrelin precursors
share almost 50% similarity in their amino-acid sequences,
and the receptors of both peptides are part of the same
family of G protein-coupled receptors and share 53%
overall amino-acid sequence identity [17]. Based upon their
structural similarity, the two peptides are now consid-
ered to be members of the new motilin-ghrelin peptide
family.
Motilin regulates the interdigestive migrating contrac-
tions (IMC), the fasted motor pattern in the gastrointestinal
(GI)tract[18].Motilin plasmalevelsincreasecyclicallyevery
90–120 minutes during the interdigestive fasting period, and
this cyclical release of motilin disappears after ingestion
of a meal. These cyclical peaks of plasma motilin are
synchronizedtostrongperistalticcontractionsinitiatedfrom
the stomach and migrating to the duodenum and small
intestine. This pattern of migrating waves is known as the
phase III contraction of IMC.
Ghrelin has also been reported to stimulate GI motil-
ity [19–22]. Ghrelin administration induces phase III-like
contractions in the rat stomach [20]. Ghrelin also induces
premature phase III contractions of IMC in the human
stomach [21]. Vantrappen et al. [23] reported that motilin
induces phase III contractions at a lower dose than ghrelin.
On the other hand, high doses of motilin [24]a n dl o wd o s e s
ofghrelin[5]stimulateGHsecretion.AsindicatedbyPeeters
[25], these results suggest that both peptides may cross-react
with their receptors.
Endogenous ghrelin has been reported to be involved
in mediating phase III-like contractions in the stomach of
rats [26]a n dm i c e[ 27]. However, we revealed that ghrelin2 International Journal of Peptides
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Figure 1: The typical four phases of IMC in the dog. Phase I:
quiescence. Phase II: phase of irregular contractile activity. Phase
III: intensive rhythmic contractions. Phase IV: rapid decline of
activity before complete quiescence.
administration did not stimulate GI motility in conscious
dogs [28]. Whether ghrelin activates GI motility in dogs and
humans is controversial. This review focuses on the capacity
of ghrelin to act on GI motility and compares the ﬁndings
with those of motilin mainly in the dog.
2.MotilinandGastrointestinalMotility
Because the motilin receptor exists as a pseudogene only in
rodents [29, 30], studies on motilin regarding GI motility
in animal models are scarce and have been limited to dogs.
Motilin is considered to be a unique hormone playing a role
intheinterdigestiveperiod,ratherthan,asinthecaseofmost
hormones, in the postprandial period. In the interdigestive
state, GI motility is characterized by cycling IMC originating
in the stomach and propagating along the small intestine.
IMCs are assumed to have an important housekeeping
role by forcefully pushing the content of the gut forward
while cleaning the bowel of debris and bacteria that would
otherwise accumulate and lead to bacterial overgrowth and
compromise nutrient absorption from the small intestine,
resulting in the sensation of hunger. The four phases of
IMC were ﬁrst described by Szurszewski [31]. Figure 1 shows
the typical four phases of IMC in the dog. Phase I is
quiescence. Phase II is irregular contractile activity. Phase III
is characterized by intense, rhythmic contractions starting
in the lower esophageal sphincter (LES) and stomach and
migrating down the small bowel to the terminal ileum.
In Phase IV, the activity rapidly declines until complete
quiescence. Soon after motilin’s discovery, it was suggested
that motilin induces hunger contractions [32]. Itoh et al.
[33] showed that the exogenous administration of motilin
initiates premature phase III contractions in the stomach
that are quite similar to the spontaneously occurring phase
III contractions in dogs. This notion is supported by a
s t u d yb yP e e t e r se ta l .[ 34], who described phase III motor
activities starting in the stomach or the upper duodenum
that are associated with plasma motilin peaks, and another
by Lee et al. [35], who reported that immunoneutralization
of circulating motilin suppresses phase III contractions.
Many observations suggest the presence of motilin
receptors on smooth muscle cells and on neurons of the GI
tract.Itohetal.[36] found that the eﬀect of motilin on phase
III activity in dogs was blocked by a 5-hydroxytryptamine-3
(5-HT3) antagonist. This ﬁnding suggests that the motilin-
induced signal may be mediated via 5-HT3 receptors on the
vagal aﬀerents. The signal is then transmitted to the stomach
via vagal eﬀerents that induce the release of endogenous
acetylcholine, since anticholinergic agents block the eﬀect
of motilin. On the other hand, in many in vitro studies,
the induction of contractility by motilin was observed to
be resistant to tetrodotoxin, which suggests that motilin
receptorsarepresentonsmooth-musclecells[37–39]andthe
contractile eﬀects of motilin are mediated through a direct
action on smooth muscle cells. Most evidence now points
to the existence of motilin receptors on nerves as well as on
muscles.
3.GhrelinandGastrointestinalMotility
As for the case of motilin, Tack et al. [21] demonstrated
that, in humans, the administration of ghrelin induces a
premature gastric phase III, which is not mediated through
the release of motilin. Unlike motilin, ghrelin also induced
phase III-like contractions in rats and mice [20, 26, 27].
These observations suggest that while the pharmacological
eﬀects of ghrelin were demonstrated, the involvement of
ghrelin in the control of normal interdigestive motility was
not.
In dogs, we revealed that an i.v. injection of synthesized
canine ghrelin did not stimulate motor activity in the
digestivetract(Figure 2),althoughitdidstimulatetherelease
of a GH [28]. Kudoh et al. [40] also reported that neither
the growth hormone-releasing peptide-2 nor ghrelin evoked
GI contractions in the interdigestive state. These results
diﬀer from those obtained with studies using rodents. It
is reasonable to expect that the action of a peptide will
change from species to species. It remains to be determined
whether ghrelin could be the surrogate of motilin in rats.
The role of endogenous ghrelin in the regulation of phase
III-like contractions remains unclear. To date, unlike the
case of motilin [34], ﬂuctuation of plasma ghrelin levels
in synchrony with phase III activity fronts has not been
reported.
4.MotilinasaProkinetic
Motilin has a therapeutic potential as a pharmacological
agent in stimulating gastric motility and accelerating gastric
emptying of foods. Itoh et al. [41] ﬁrst showed that
erythromycin, a macrolide antibiotic, interacts with the
motilin receptor and mimicked the eﬀect of motilin on GI
motility during the interdigestive state in dogs. In addition,
in humans, erythromycin induces phase III activity [42], and
the eﬀect is dose-related in healthy volunteers and patients
with diabetic gastroparesis [43]. Erythromycin derivatives
devoid of antibiotic activity but with strong aﬃnity for
motilin receptors, also called motilides [44], were clinicallyInternational Journal of Peptides 3
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Figure 2: Examples of the eﬀect of canine ghrelin at 1 and 10μg
kgBW
−1 on the myoelectrical activity in a conscious dog, measured
at a gastric body (GB), gastric antrum (GA), duodenum (D),
jejunum (J-1 and J-2), and colon (C). Ghrelin did not alter the
interval and amplitude of phase III (1μgk gB W
−1)( f r o m[ 28]).
tested. Clinical studies of ABT-229, one of the motilides,
demonstrated the acceleration of gastric emptying in healthy
volunteers;however,ABT-229failedtoimprovesymptomsin
patients with functional dyspepsia and diabetic gastroparesis
[45, 46]. Disappointing results with ABT-229 decreased the
interest in this ﬁeld of research. However, it was pointed
out that several factors associated with the drug (long half-
life and/or tachyphylaxis [47] and possible eﬀect on gastric
accommodation [48–50]) and the study design (selection
of patient population [51]) may have contributed to the
negative outcome [52].
Anewmotilide,GM-611ormitemcinal,ledtopromising
new results. Takanashi et al. [53] conﬁrmed mitemcinal
as a selective and full motilin receptor agonist in in vitro
pharmacological studies. Similarly to the case of motilin,
intravenous administration of mitemcinal in dogs [54]
stimulated interdigestive, as well as digestive, gastroduodenal
motor activity, and its eﬀect was blocked by the motilin-
receptor antagonist GM-109. Colonic motility in dogs [55]
could also be stimulated by mitemcinal given orally. Ran-
domized controlled trials in 392 insulin-requiring diabetics
revealedthatsymptomsattributabletogastroparesiscouldbe
ameliorated with 10mg mitemcinal twice daily than with a
placeboandwithoutinducingsigniﬁcantadverseeﬀects[56].
5.Ghrelinasa Prokinetic
Masuda et al. [19] suggested that ghrelin could stimulate
gastric contractions in rats. Trudel et al. [57]d o c u m e n t e d
that ghrelin accelerates gastric emptying and the small
intestinal transit of a liquid meal and is a strong prokinetic
agent capable of reversing the postoperative gastric ileus in
conscious rats. Poitras et al. [58] conﬁrmed that the ghrelin
analog RC-1139 is a potent gastrokinetic in rat: it reversed
gastric postoperative ileus, even in the presence of opiates.
The gastrokinetic capacity of ghrelin had been well doc-
umented in the rodent. Trudel et al. [59] demonstrated that,
as found earlier in rodents, ghrelin accelerates the normal
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Figure 3:Eﬀects ofcanine ghrelinongastricemptying inconscious
dogs. Saline and canine ghrelin were administered intravenously.
Each symbol represents the mean ± S.E.M. every 15 minutes in
three dogs. Diﬀerences were not signiﬁcant (P> .05) (from [28]).
gastric emptying of a meal and was a potent prokinetic agent
that improved postoperative gastric ileus in dogs. On the
contrary, we [28] showed that an i.v. injection of ghrelin did
not accelerate gastric emptying in dogs (Figure 3). To date,
encouraging results of the gastrokinetic capacity of ghrelin
in dogs are few.
In humans, Binn et al. [60] showed that an i.v. ghrelin
injection accelerated gastric emptying of a meal even in the
presence of deﬁcient gastric innervation. Tack et al. [61]
obtained similar results in which, in idiopathic gastroparesis,
the administration of ghrelin enhanced gastric emptying
and improved meal-related symptoms. These observations
suggest the potential for ghrelin as a prokinetic. TZP-101,
a synthetic ghrelin-receptor agonist, has been shown to be
an active gastrokinetic agent in rats [62] and has already
been tested in humans [63]. However, it seems diﬃcult
to believe that plasma ghrelin could play a physiological
role in these digestive physiological events. Most evidence
indicates that ghrelin plasma levels are high during the
fasting period and decrease after meal ingestion. Most GI
peptides increase after a meal. Motilin and ghrelin are
the only hormones known to decrease in the postprandial
period [64]. The observed biological action of the peptide,
stimulation of meal gastric emptying, appears to be in con-
tradiction with its endogenous release being suppressed after
eating.
6. Conclusion
Ghrelin is of great interest, as is motilin, to the GI phys-
iologist. The value of ghrelin as a prokinetic agent may
soon be revealed. However, the physiological roles of ghrelin,
especially in dogs and humans, need to be clariﬁed.4 International Journal of Peptides
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